AstraZeneca PLC

DB:ZEGA Stock Report

Market Cap: €248.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AstraZeneca Past Earnings Performance

Past criteria checks 5/6

AstraZeneca has been growing earnings at an average annual rate of 32.8%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 14.2% per year. AstraZeneca's return on equity is 20.5%, and it has net margins of 16.2%.

Key information

32.76%

Earnings growth rate

29.53%

EPS growth rate

Pharmaceuticals Industry Growth7.33%
Revenue growth rate14.23%
Return on equity20.46%
Net Margin16.17%
Next Earnings Update10 Feb 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AstraZeneca makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:ZEGA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2558,1279,39919,22813,573
30 Jun 2556,5018,29519,32013,058
31 Mar 2554,9827,77219,39712,559
31 Dec 2454,0737,03519,45312,243
30 Sep 2451,2066,49518,76511,793
30 Jun 2449,1336,44018,40611,206
31 Mar 2447,6116,33118,46210,816
31 Dec 2345,8115,95518,02510,373
30 Sep 2344,9945,89618,2589,922
30 Jun 2344,4856,16317,7329,782
31 Mar 2343,8404,70517,4259,642
31 Dec 2244,3513,28817,4609,669
30 Sep 2245,1552,04017,4259,134
30 Jun 2244,038-1,25317,2329,184
31 Mar 2241,487-1,06315,6238,535
31 Dec 2137,41711214,6738,049
30 Sep 2132,8161,47113,6517,831
30 Jun 2129,5283,77112,2706,888
31 Mar 2127,5833,97711,8086,448
31 Dec 2026,6173,19611,5865,901
30 Sep 2025,8712,49710,9095,653
30 Jun 2025,6992,14811,3675,504
31 Mar 2025,2471,52211,6525,471
31 Dec 1924,3841,33511,4385,349
30 Sep 1924,1372,05612,1345,442
30 Jun 1923,0712,18811,3175,338
31 Mar 1922,4032,40810,8805,313
31 Dec 1822,0902,15510,8225,299
30 Sep 1821,4502,4229,8505,251
30 Jun 1822,3422,6779,8855,378
31 Mar 1822,2382,8049,6255,358
31 Dec 1722,4653,0019,4065,455
30 Sep 1722,2733,5429,2515,507
30 Jun 1721,7403,8709,0495,501
31 Mar 1722,2923,3909,6455,586
31 Dec 1623,0023,4999,7435,679
30 Sep 1623,8162,46510,4645,790
30 Jun 1624,0622,22110,7845,800
31 Mar 1624,7662,92110,7965,808
31 Dec 1524,7082,82511,0245,660
30 Sep 1525,0251,69611,7965,392
30 Jun 1525,6891,18012,2555,361
31 Mar 1526,1441,27912,2805,180

Quality Earnings: ZEGA has a large one-off loss of $3.2B impacting its last 12 months of financial results to 30th September, 2025.

Growing Profit Margin: ZEGA's current net profit margins (16.2%) are higher than last year (12.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ZEGA's earnings have grown significantly by 32.8% per year over the past 5 years.

Accelerating Growth: ZEGA's earnings growth over the past year (44.7%) exceeds its 5-year average (32.8% per year).

Earnings vs Industry: ZEGA earnings growth over the past year (44.7%) exceeded the Pharmaceuticals industry 9.8%.

Return on Equity

High ROE: ZEGA's Return on Equity (20.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/04 13:14
End of Day Share Price 2026/01/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AstraZeneca PLC is covered by 57 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research